Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, an…
| Métrica | BOI.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 71.1% | 57.4% | +13.7% |
| Operating Margin | 11.9% | -34.4% | +46.3% |
| Net Margin | 8.4% | -32.5% | +40.8% |
| FCF Margin | 9.1% | -12.6% | +21.7% |
| ROE | 8.0% | -39.2% | +47.2% |
| ROA | 5.7% | -30.9% | +36.6% |
| Current Ratio | 3.12 | 2.73 | +0.39 |
| Debt / Equity | 0.02 | 0.28 | -0.26 |
| Tendencia (Piotroski) | FY22 | FY21 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 5.7% | — |
| ✓Flujo de caja operativo positivo | €59M | €33M |
| ✓Rentabilidad sobre activos al alza | 5.7% | 3.7% |
| ✓Caja operativa/activos supera al ROA | 7.4% | ROA 5.7% |
| ✗Menos deuda a largo plazo | 1.5% | 0.3% |
| ✓Mejor liquidez (ratio corriente) | 3.12 | 2.86 |
| ✓Sin aumentar el nº de acciones | 17M | 18M |
| ✗Margen bruto al alza | 71.1% | 72.0% |
| ✓Rotación de activos al alza | 0.68 | 0.59 |
| Calidad del negocio | FY22 |
|---|---|
| ✗Margen FCF > 10 % | 9.1% |
| ✗ROCE > 10 % | 10.0% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 3.1% |
BOIRON cotiza a 18.60 EUR y tiene una capitalización bursátil de €323M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud